Global Expertise. Local Execution.
Backed by a global ecosystem of tailored solutions for 45 local markets.
BE ACCELERATED
It’s time for some new thinking
Global Launch Execution Platform Accelerating Access to patients, markets,
KOLs, HCPs, talent, data and capital for Rare Disease and biotech innovations
ABOUT subrosa
Who we are
With patients at the forefront of everything we do, subrosa Health & Capital, a strategy and execution services group, enables rare disease, biotech and healthcare companies to gain accelerated access to any market, to patients, to KOLs & HCPs, to elite talent and to capital – from early drug development to launch to lifecycle management through a worldwide connected, intelligent and trusted ecosystem.
subrosa combines strategic market access optimization, end-to-end medical & commercial launch services, unique clinical programs for early patient identification, holistic patient solutions, recruitment, commercial partnering and funding under one roof to meet core needs of the headquarters, shorten timelines, achieve commercial goals faster and leave no patient behind.
BE ACCELERATED
WHO WE ARE
Vision & Mission
Science is our passion, in our genes, we speak the language and know the local markets; we at subrosa Group want to become the leading clinical and commercial catalyst for breakthrough therapies, accelerating the path from clinical to patient impact.
The urgency of now! Move fast, act decisively.
As time is crucial in startup and launch situations, we are constantly on the move, relentless in our determination to speed up all processes, enlarge our range of services and expand our pharma leaders-, KOL- & capital-networks to support rare disease and biotech headquarters with their core needs:
To secure funds, optimize & execute the most effective global commercialization strategy, to recruit patients years earlier than today’s standards, secure their treatment & adherence and supply them even if the drug is not authorized in a market.
Measurable impact right when and where it matters most, for long-term win-win partnerships
Why subrosa Exists
It started with a new way of thinking
A statement from Prof. Dr. Dr. Arndt Rolfs & Georg Nagl on why we built subrosa.
Curious?
Click here
Viewed from a broader, helicopter perspective, we feel a market in transition, where pricing and policy pressures, including the continued implications of Most Favored Nation (MFN) frameworks, are converging with rapid advancements in data, AI, and evolving distribution models.
Currently, a substantial number of drugs for innovative therapies and diagnostics are being developed both in the US and, increasingly, abroad—primarily in China, the APAC region, and Europe. These products call for global commercialization by both established pharmaceutical companies and a dynamic, growing landscape of startups.
These challenges and opportunities are why we established subrosa Health & Capital nine years ago to create a global solutions ecosystem that spans the entire product lifecycle and patient journey. Our goal: to achieve the greatest impact for those most in need: startup companies who often face limited access to markets, financial resources, human capital & infrastructure and rare disease patients.
Today, we are proud to have fulfilled our mission and left the “stealth mode”. subrosa stands as a trusted partner, making global development and commercialization simpler, faster, and less risky, ensuring that no patient is left behind.
WHO WE ARE
Our Core Values
We strive to uphold our core values every day – and we recognize and celebrate these ideals together in many ways throughout the year.
Respectful Diversity
We create an environment of awareness and mutual respect -
where different viewpoints and talents are the foundation of our global culture.
Innovation & Integrity
We have a bold vision. We are dynamic and
creative in everything we do, providing hand-tailored
solutions while upholding the highest standards of ethical conduct.
XCLR8ED Speed
Time is crucial. We are constantly on the move, relentless in our
determination to speed up every process - and achieve medical and commercial goals faster.
Commitment & Reliability
We are committed to excellence and dedicated to the long-term success
of our clients - by delivering on promises, taking decisive action, and ensuring accountability.
Make an Impact
We are just a small light in the big biotech universe but we work hard
to make a real impact, improving the lives of undiagnosed patients and illuminating the unseen.
Culture is how Monday morning feels on Sunday night.
Who we are
Latin Roots Meet Scientific Rigor
The Meaning of subrosa
According to legend, the expression Sub Rosa Dictum (Latin for “spoken under roses”) comes from the following incident: Cupid, the god of sensuality and love, sent some roses to Harpocrates, the god of secrecy, as an expression of his request to keep the love affair of his mother Venus hidden.
In ancient Rome, the Vatican and the High Middle Ages a fresh rose on the ceiling or a rose ornament at the council tables indicated that discussions are conducted discreetly, and in “The Da Vinci Code” by Dan Brown, “subrosa” religious messages, hidden for centuries, e.g., that Maria Magdalena herself is the true Holy Grail, must be decoded by the protagonists.
In this narrative, the meaning of the rose can be traced as a symbol of secrecy and a subrosa meeting shall be conducted discreetly typically to protect sensitive information.
Our solutions are powered by global networks, deep scientific & commercial expertise, unique insights and proven experience. But what truly sets us apart?
The part you don’t see. The silent edge. The confidential layer.
That’s subrosa, we stand for discretion, depth, and discovery. In an environment where rare disease patients are mostly beneath the surface, subrosa operates “under the rose”, quietly but powerfully uncovering insights, illuminating the unseen and identifying new patient populations.
While the pace of change is increasing, subrosa Group delivers confidential and sustainable impact for the global commercialization - as a trustee of our biotech, startup and venture capital clients.
Illuminating the unseen
WHO WE ARE
Executive Board
Experience matters
MICHAEL HARVEY
Chief Business Officer
CEO Harvey & Nagl Health
CEO Harvey & Nagl Health
British, environmental scientist, >25 years of experience within the biotech-pharma sector. Specialist in developing complex end-to-end solutions from drug development to all stages of commercialization with links to financing.
Personal advisor to a number of CEOs & boards across the biotech sector; extensive global industry network.
Since 2023: shareholder subrosa Health Group and subrosaLINKS.
2011–present: co-founder of Links Life Sciences, a global boutique executive search and consultancy service to biotech.
2010–2011: MH Consulting for various pharma organizations (MSD, Shire etc.).
1997–2010: various leadership, sales, training and management positions within pharma.
HEDIE NEUGEBAUER
Head of People & Culture
GM subrosa Health & Capital
GM subrosa Health & Capital
German, psychologist with 10 years of experience in Recruitment & Executive Search within the pharmaceutical industry.
07/2019 to present: heading the global Executive Search (co-leading) Recruitment & Human Capital Services (incl. Temporary Employment) teams at subrosa Health & Capital GmbH. Responsible for filling permanent and interim roles, with a keen ability to align with client needs and business objectives — ensuring the right people are brought together. Well-versed in the fast-paced environments of EMEA startups & small biotechs.
2015–06/2019: Ashfield Healthcare GmbH — various positions in Recruitment & Executive Search.
PROF. ARNDT ROLFS
Chief Medical Officer
CEO subrosa OmicsAI
CEO subrosa OmicsAI
German, medical expert, Neurologist & Psychiatrist. Globally recognized authority with an extensive C-level network in rare genetic diseases & innovative biomarkers, with >20 years of experience founding companies in the biotech and healthcare sector.
>400 peer-reviewed scientific papers; >40 patents; medical expert for FDA & EMA.
2023 to present: shareholder subrosa Health Group; founder & shareholder subrosa OmicsAI. Managing Director RCV Rare Disease Consulting GmbH; CEO & co-founder of Agyany Pharma Ltd. (Israel, Zug/CH).
2020–2023: CEO/founder of Arcensus GmbH.
2005–2020: CEO/founder of Centogene AG (IPO Nasdaq: CNTG 10/2019).
2008–2018: Director of the AKOS-Institute, University of Rostock, Germany.
GEORG NAGL
Chief Executive Officer
subrosa Health & Capital
subrosa Health & Capital
German, Micro-Biologist, >25 years of experience in biopharma. “Entrepreneur of the Year” (E&Y), winner “Excellence in Financing Growth” (EU Commission).
Investor in biotech & Digital Health. Personal advisor to several CEOs; member of Advisory Boards of PE, biotech & startup companies. Extensive global C-level network in biopharma & Capital.
2010 to current: shareholder subrosa Health Group.
1999–2010: pharmexx (CSO) — CEO & main shareholder. One of the most successful small caps in EU, World’s No.1 CSO (5,500 employees, 21 countries); divestment in 2010, now “Ashfield/Inizio”.
1993–1999: sales and management roles in biopharma (Zeneca, BMS, ...).
YASMIN WALKER
Head of Operations
subrosa Health & Capital
subrosa Health & Capital
Bavarian, with Indian ancestry and strong ties to the USA. Biologist & marketeer (University of Leicester graduate) with 20 years of experience in the biotech-pharma & diagnostics market.
Specialist in supporting startups in specialty and rare disease to build out their structure across the US, North America and Europe.
Former Global Head of Operations & Talent Acquisition at TMC (Tardis Medical Consultancy) and part of the leadership team. Founder of HiO Agency (US executive finders) and RecruLent GmbH (European recruitment agency).
Designed and organized Assessment Centers across Europe, North America and LATAM to find top talent supporting earlier rare-disease patient identification and timely treatment.
Established the first sponsor-representing clinical teams in Asia and MENA for Phase II–IV trials. Seconded to UPSHE / AC Medical Japan on outsourced clinical, medical and commercial projects.
Former Medical Advisor & Key Account Manager in pharma — bridging clinical, medical and commercial.
DR. FRANK BAUER
Chief Marketing Officer
CEO 42.health
CEO 42.health
German, Chemist, more than 30 years of sales & marketing experience in the pharmaceutical industry.
2015 to current: founder and shareholder of 42.health and pharmxpert GmbH — providing medical & commercial remote, hybrid or in-person channels to HCPs & patients, and global sales & marketing solutions.
2005–2015: pharmexx GmbH / Ashfield Healthcare GmbH — several positions in the international management team incl. EVP Global Marketing, Managing Director Celesio Manufacturing Solutions GmbH, Managing Director Germany.
1992–2004: AstraZeneca — sales & marketing activities, Marketing Director CNS Business Unit.
CHENTHIR KUMARAN
Head of Managed Care
CEO subrosa APAC
CEO subrosa APAC
Indian, Business Transformation & Disruptive Marketing Specialist with nearly 40 years of experience in senior leadership roles. Focused on rapid turnaround & bottom-line growth.
Advisor, trainer & coach for many young pharmaceutical organizations. Currently on a mission to orchestrate a new ecosystem unlocking market potential for rare disease & Orphan Drug companies in Asia by integrating PAOs, healthcare providers, patients, policymakers & payers.
Currently President of subrosa India & CEO of Healing Wings Foundation.
1985–2000: various leadership roles in MNC pharma organizations (Bayer, Daiichi Sankyo).
2001–2014: Co-founder & Managing Director of Pharmexx India.
2014–2024: Founder & Majority Shareholder of Maven Marketing CSO.
2024 to current: subrosa India — President.
DR. ARMIN RATH
CEO subrosa Health & Capital US
Head of Global Market Access
Head of Global Market Access
Dr. Armin Rath is a senior life-sciences executive with over 20 years of leadership experience across biotech and pharma, spanning the US and European markets. He has built and scaled companies from inception to commercialization, with deep expertise in oncology, immunotherapy, neurodegeneration, and rare disease.
A recognized authority in market access, pricing, and reimbursement strategies, Dr. Rath has successfully led AMNOG negotiations, developed EU/US launch strategies, and secured multi-million-dollar licensing, JV and M&A deals.
His track record includes P&L leadership, IPO readiness, and driving global partnerships while ensuring sustainable value creation.
LILY LEI
Head of Distribution Business
CEO subrosa Health China
CEO subrosa Health China
Ms Lily Lei is a seasoned leader in the pharmaceutical industry, with over 20 years of leadership experience in the sector. In 2003, she founded MECECHEM (WUXI) CO., LTD., whose business operations span Europe, Africa, Asia, Central and South America. The company’s product portfolio covers multiple fields including dermatology, oncology, cardiovascular medicine and gastroenterology. Lily is currently focusing on utilising the special policy for pharmaceuticals and medical devices in Hainan, China, to introduce internationally advanced medicines and medical devices, including rare disease products for subrosa Health China.
2003–present: Founder and General Manager of MECECHEM, a pharmaceutical company, leading import and export projects for pharmaceuticals and medical devices, with operations spanning Europe, Africa, Asia, Central and South America.
2021 to present: Founded HAIXI HEALTH, holding a GSP (Good Supply Practice) licence, with a modern logistics warehouse, an electronic sorting system, and an Enterprise Resource Planning & Warehouse Management System.
2023 to present: Co-founded Jiangsu Coexcel Biotech Co., Ltd., a Marketing Authorisation (MA) holder for pharmaceutical products and a professional R&D centre serving as a leading platform for advanced topical pharmaceutical preparations (aerosols, foams, etc.).
TOMAS GUINCHARD
Head of Patient Support
CEO subrosa adxto Nordics
CEO subrosa adxto Nordics
2007 to present: Founder and CEO of Adxto Group and Managing Director of Adxto Care AB, leading healthcare initiatives across the Nordics with focus on patient support services, recruitment, and decentralized healthcare solutions.
2008 to present: Founder and Managing Director of Adxto Singapore, Thailand and Philippines, establishing healthcare and outsourcing operations in Asia.
2017–2023: Founder of the pharmaceutical company Frostpharma, successfully divested to private equity.
1995–2007: Founder and CEO of Kinchard Group, establishing pharmaceutical and healthcare service operations throughout the Nordic region.
NIEK STANDER
Head of subrosa Capital
Expert Licensing
Expert Licensing
South African, Economist, more than 30 years of experience in pharmaceutical and other industries: finance, strategic planning, sales & marketing organizations and group strategy.
2018 to current: shareholder subrosa Capital — leads the subrosa Consulting, Global Partnering & M&A teams.
Strategic advice: strategy review, market entry and portfolio reviews, financial planning and financing / investor support.
2001–2018: Astellas Pharma — Executive VP Commercial EMEA, Managing Director Germany, CFO EMEA.
1992–2001: various audit and consulting roles at Ernst & Young and PwC.
MICHAEL KRING
Head of Funds & M&A
Expert Early Biotechs
Expert Early Biotechs
German, well-positioned CFO with an active network among life-sciences & tech investors in Europe. More than 20 years of professional experience working alongside VC investors and >350 startup projects.
Supported >40 projects within the framework of EXIST Research Transfer & GO-Bio-Excellence Grants programs. Held various board & C-level management positions in >50 startup companies incl. SuppreMol, ETHRIS, BioNTech, miRdetect, ActiTrex etc.
Active as business angel, founder, shareholder & investor in >25 startup companies and >150 supported financing rounds.
Financial services provider to various companies & corporations, and co-author of multiple articles and books focused on entrepreneurship and startups.
WHO WE ARE
We open doors! Our Global Networks
subrosa Group’s clinical, medical and commercial experts have XCLR8ED access to decision-making local and global networks making things faster for your global commercialization.
Markets
409 experts on the ground in 29 offices across 21 countries deliver services in 45 markets through networks to decisive stakeholders of the local healthcare ecosystems.
Patients & PAOs
We identify, support, treat and register rare disease patients and we keep them adherent. Collaboration with PAOs and screening programs additionally feed our proprietary patient genome database, one of the world’s largest.
Key Opinion Leaders
Our teams work with KOLs for Rare and Genetic-based indications intensively for decades in clinical trials, patient identification, Market Access, Advisory Boards and patient advocacy projects globally. If there are none in an ultra or nano rare indication, we will build them.
Healthcare C-Suites
Both, decades of personal relationships of our Executive Board members and executive search, partnering, funding and M&A activities made us trusted partners of founders, shareholders and C-level executives of global biopharma innovators.
Healthcare Professionals
Our proprietary HCP-database is built and actualized by data from numerous deployed medical CTL, MSL teams, commercial KAM and Rep-Salesforces and Patient engagement forces.
Authorities
We work together with a broad range of local and regional authorities on the way from drug development to patient; e.g. for study & drug, regulatory (EAPs), reimbursement and funding approvals.
Talent
With offices across the globe we have long-lasting relationships and access to executives (HNC US, HNH Intl) and talent (subrosa Health) to acquire the ones you need to succeed across all roles in a drug’s lifecycle: permanent, ad interim or contingent.
Co-development & License Partners
Through our pharma network and years of due diligences of licensing & distribution companies in all global markets we support you finding co-development and commercialization partners. This is an important part of our commercial end-to-end approach.
Capital
Collaborating with business angels, family offices, VC, PE and pharma (strategic investor) authorities and PAO networks is daily business of our subrosa Capital teams to support raising funds and grants.
Further Networks
rare disease clinical sites powered by our intensive global KOL-network also in China, India, APAC, GCC and CIS region. Our Payer and ex-Payers network makes it easier for us to estimate prices and timelines in our go-to-market modeling.
Built for speed. We address the main stakeholders of local & regional healthcare ecosystems
WHO WE ARE
Make an Impact & Help More Rare Disease Patients
Our Strategic Collaboration with Healing Wings Foundation
HWF, a global Patient Advocacy Organization, is a trusted partner for rare disease patients, physicians, payors and authorities — to leave no patient behind.
Rare Disease Patient Support
- Psychological support
- (Genetic) Counseling
- Awareness & Education
- Financial support through Crowdfunding and CSR
- Community Building
- Patient registry
Research Involvement
- Input to Patient Reported Outcomes (PROs)
- Contributing to clinical trial designs
- Support with patient recruitment for clinical rare disease studies
- Screening programs for undiagnosed patients
Advocacy & Policy
- Influencing reimbursement policies
- Approval pathways
- Legislation
- Advisory Committees
We’re working toward a future where every patient can find a path forward — even when no drug exists yet.
We push into areas where it’s genuinely difficult: helping patients with “advanced” ultra‑rare and nano‑rare conditions, where originators typically lack a sustainable business model.
Through our collaboration with Healing Wings Foundation, we support PAO-led patient registries and rare disease research — always with informed consent and local data-protection compliance.
Rare< 1:2,000
Ultra-rare< 1:50,000–100,000
Nano-rare< 1:1,000,000
WHO WE ARE
Our Global Footprint
Local scientific teams. Global ecosystem. Trusted.
0Offices
0Countries
0Markets
0Experts
As of April 2026
We leave no patient behind, regardless of where they live.
CAMBRIDGE
MIAMI
ZUG
MUNICH
MANNHEIM
LUNENBURG
VIENNA
LONDON
UXBRIDGE
BARI
MADRID
AMSTERDAM
STOCKHOLM
VILNIUS
WARSAW
LJUBLJANA
TBILISI
DUBAI
JERUSALEM
WUXI
HAINAN
CHENNAI
SINGAPORE
MEXICO CITY
SAO PAULO
BUENOS AIRES
Who we are
Why subrosa?
subrosa is the worldwide Health & Capital platform that unites intelligence, networks, and execution - identifying patients, opening markets, connecting capital, and deploying the teams that turn rare-disease and specialty-biotech science into real-world impact.
True 360° Partner
From fundraising and patient recruitment to therapy access — end-to-end under ONE roof.
Access to Main Stakeholders
Our global networks of patients, KOLs, HCPs, pharma C-Suite, payers, authorities & capital help you achieve your medical & commercial goals faster.
We Really Know the Science
The know-how of our world’s leading scientists, our KOL network, and the insights from our proprietary early-patient genome database give us a competitive advantage.
Our Culture
We are committed to excellence, accountable, and dedicated to the long-term success of our clients.
Privately Owned
Owned by entrepreneurs, subrosa keeps the promise and goes the extra mile to find the right solution for you. Always.
Every capability. One platform. One accelerated path.
We bridge your gaps
Trusted by leading life-science companies worldwide
AbbottAbbVieAbdiAbnobaAccordActelionActoBioAdvanzAdverum BioAegleaAgendiaAgiosAidianAimmuneAkceaAlbireoAlexionAlimeraAllerganAlmirallAlnylamAmarinAmgenAmicusAmrytAmylyxAngeliniAntaresApellisApontisArenaArgenxArmoArvelleAscendisAspenAstellasAstraZenecaAutolusAuxiliumAviaAvidityAzur PharmaB.BraunBasileaBausch & LombBavarian NordicBaxaltaBaxterBayerBeamBeiersdorfBeiGeneBeOneBesinsBIALBioCrystBiogenBiomarinBiometBioNTechBioprojetBiovailBluebird bioBlueprintBMSBoehringer IngelheimBoironBoston ScientificCamarusCarl ZeissCephalonChiesiChugaiClovisColgateCrineticsCSLcurrentzzCytokineticsDaiichi-SankyoDanoneDecipheraDenaliDiurnalDompeDr. FalkEisaiEsteveEUSAExact SciencesFerrerFerringFreseniusFujisawaGalapagosGaldermaGE HealthcareGedeon RichterGentiliGileadGrifolsGrünenthalGSKGTx Inc.Guardant HealthGW pharmaceuticalsHAL AllergieHaleonHalozymeHexalHorizonIdorsiaIncyteInterceptIntrexonIpsenItalfarmacoITF PharmaITMJ&JKaro PharmaKiadisKiteKlingeKyowa KirinLeo PharmaLigandLillyLindeLohmann & RauscherLundbeckLupinLyrixLyvyenLórealMadrigalMallinckrodtMead JohnsonMedacMediceMedImmuneMedtronicMenariniMerck SeronoMereoMerzMetrioPharmMiratiMirumMithraMSDMundipharmaMylanMyriadMölnlyckeNeopharmedNestléNikonNiproNordic PharmaNorgineNovartisNovavaxNovo NordiskNovocureOlympusOncoBetaOncopeptidesOnoOrionOrphalanOtsukaOvivaP&GPaul HartmannPfizerPharma&PharmacosmosPhytogenPierre FabrePiramalPortolaPrecigenProthenaQLTReckittRecodartiRegeneronResMedRevolution MedicinesRhythmRocheSageSalixSandozSanofiSantenSareptaScholar RockSeagenSenturiSeqirusServierShireSiemens HealthineersSmith & NephewSOBISpringsworksStebaStemlineStragenStridesStrykerSunovionTakedaTDSTenxTesaroTetrisTevaTherabelThermo FisherThromboGenicsTiberTorrentUS SurgicalUCBUnileverUriachValeantValnevaVernalisVertexViatrisVicuronViforViiVVygonYamanouchiZambonZogenixAbbottAbbVieAbdiAbnobaAccordActelionActoBioAdvanzAdverum BioAegleaAgendiaAgiosAidianAimmuneAkceaAlbireoAlexionAlimeraAllerganAlmirallAlnylamAmarinAmgenAmicusAmrytAmylyxAngeliniAntaresApellisApontisArenaArgenxArmoArvelleAscendisAspenAstellasAstraZenecaAutolusAuxiliumAviaAvidityAzur PharmaB.BraunBasileaBausch & LombBavarian NordicBaxaltaBaxterBayerBeamBeiersdorfBeiGeneBeOneBesinsBIALBioCrystBiogenBiomarinBiometBioNTechBioprojetBiovailBluebird bioBlueprintBMSBoehringer IngelheimBoironBoston ScientificCamarusCarl ZeissCephalonChiesiChugaiClovisColgateCrineticsCSLcurrentzzCytokineticsDaiichi-SankyoDanoneDecipheraDenaliDiurnalDompeDr. FalkEisaiEsteveEUSAExact SciencesFerrerFerringFreseniusFujisawaGalapagosGaldermaGE HealthcareGedeon RichterGentiliGileadGrifolsGrünenthalGSKGTx Inc.Guardant HealthGW pharmaceuticalsHAL AllergieHaleonHalozymeHexalHorizonIdorsiaIncyteInterceptIntrexonIpsenItalfarmacoITF PharmaITMJ&JKaro PharmaKiadisKiteKlingeKyowa KirinLeo PharmaLigandLillyLindeLohmann & RauscherLundbeckLupinLyrixLyvyenLórealMadrigalMallinckrodtMead JohnsonMedacMediceMedImmuneMedtronicMenariniMerck SeronoMereoMerzMetrioPharmMiratiMirumMithraMSDMundipharmaMylanMyriadMölnlyckeNeopharmedNestléNikonNiproNordic PharmaNorgineNovartisNovavaxNovo NordiskNovocureOlympusOncoBetaOncopeptidesOnoOrionOrphalanOtsukaOvivaP&GPaul HartmannPfizerPharma&PharmacosmosPhytogenPierre FabrePiramalPortolaPrecigenProthenaQLTReckittRecodartiRegeneronResMedRevolution MedicinesRhythmRocheSageSalixSandozSanofiSantenSareptaScholar RockSeagenSenturiSeqirusServierShireSiemens HealthineersSmith & NephewSOBISpringsworksStebaStemlineStragenStridesStrykerSunovionTakedaTDSTenxTesaroTetrisTevaTherabelThermo FisherThromboGenicsTiberTorrentUS SurgicalUCBUnileverUriachValeantValnevaVernalisVertexViatrisVicuronViforViiVVygonYamanouchiZambonZogenix
Built for speed
We don’t promise what we might not be able to keep.